Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

UroGen Pharma (URGN) Shares Outstanding (Weighted Average) (2016 - 2025)

UroGen Pharma (URGN) has disclosed Shares Outstanding (Weighted Average) for 10 consecutive years, with $48.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 12.22% year-over-year to $48.1 million, compared with a TTM value of $48.1 million through Dec 2025, up 12.22%, and an annual FY2025 reading of $48.1 million, up 12.22% over the prior year.
  • Shares Outstanding (Weighted Average) was $48.1 million for Q4 2025 at UroGen Pharma, roughly flat from $48.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $48.1 million in Q4 2025 and bottomed at $22.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $32.0 million, with a median of $26.1 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) increased 1.46% in 2021, then surged 65.31% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $22.3 million in 2021, then grew by 2.06% to $22.8 million in 2022, then grew by 26.43% to $28.8 million in 2023, then skyrocketed by 48.7% to $42.9 million in 2024, then rose by 12.22% to $48.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for URGN at $48.1 million in Q4 2025, $48.1 million in Q3 2025, and $47.7 million in Q2 2025.